Catalyst Radar
The forward catalyst calendar, fused with the signals no other tracker shows — insider buying, congressional trades, dilution risk, institutional flow and unusual moves — ranked by how many independent signals converge on each event. Every signal is a verifiable fact or a calibrated, self-graded model output. Intel to research, not financial advice.
229
Catalysts tracked
35
Converging setups
1
FDA decisions
Showing 60+ catalysts · 229 tracked
Every signal here is a verifiable fact (SEC filings, congressional disclosures, observed price/volume) or a calibrated, self-graded model output (see our track record). This is intel to research, not financial advice — no buy/sell recommendations or price targets. Estimated dates are marked “(est.)”.
Run-up Edge
A different lens: catalysts ranked by the systematic pre-catalyst run-up — biotech stocks have historically drifted ~+2.6% median (56% positive) from ~J-90 to ~J-3. This is an average edge across many events, not a per-stock forecast, and it's historically flat in the final ~2 weeks. It does not predict the binary clinical outcome.
What is the Catalyst Radar?
Biotech stocks move on binary events — FDA decisions, clinical trial readouts, advisory committee votes. The Catalyst Radar tracks every upcoming catalyst and layers on the data signals that usually only show up in scattered, paywalled sources: SEC Form 4 insider buying and selling, congressional stock disclosures, equity-raise (dilution) risk, 13F institutional flow, short interest, and unusual price/volume moves our detector flags. When several independent signals converge on the same upcoming event, that's worth a closer look.
How to read it
- Signal chips — each is a fact: who bought, how much, when; or a calibrated model read.
- Converging setups — events where 2+ independent signals stack. Rare by design.
- Estimated dates — readouts with month-level dates are marked “(est.)” — never overstated as confirmed.
This is research intelligence, not financial advice. We never tell you to buy or sell, and we don't publish price targets. Model outputs are calibrated and graded in public. Always do your own research.
Frequently asked questions
What is the Catalyst Radar?
A forward calendar of upcoming biotech catalysts (FDA decisions, clinical trial readouts, advisory committees) where each event is paired with the data signals around it: insider buying and selling, congressional trades, equity-raise (dilution) risk, institutional 13F flow, short interest, and unusual price or volume moves. Events are ranked by how many independent signals converge.
What signals does the Catalyst Radar track?
Six independent signal types per catalyst: SEC Form 4 insider buying/selling, congressional stock disclosures, model-scored dilution (equity-raise) risk, institutional accumulation from 13F filings, short interest as a percent of float, and unusual price/volume moves flagged by a detector. Each is a verifiable fact or a calibrated, self-graded model output.
What is a converging setup?
A catalyst where two or more independent signals stack on the same upcoming event. Convergence is rare by design, so these are highlighted at the top of the board as the highest-attention situations to research.
Is the Catalyst Radar free?
The forward catalyst board and the count of signals on each event are free. The full intel stack (the signal values, the AI Verdict, comparables, dilution and detected-move detail) is part of the Pro plan.
Is this financial advice?
No. The Catalyst Radar presents verifiable facts and calibrated, self-graded model outputs for your own research. It never tells you to buy or sell and publishes no price targets. Always verify against FDA.gov, SEC EDGAR, ClinicalTrials.gov and company filings.